RESUMEN
2,3-Butanediol (2,3-BD) can be produced at high titers by engineered Saccharomyces cerevisiae by abolishing the ethanol biosynthetic pathway and introducing the bacterial butanediol-producing pathway. However, production of 2,3-BD instead of ethanol by engineered S. cerevisiae has resulted in glycerol production because of surplus NADH accumulation caused by a lower degree of reduction (γ = 5.5) of 2,3-BD than that (γ = 6) of ethanol. In order to eliminate glycerol production and resolve redox imbalance during 2,3-BD production, both GPD1 and GPD2 coding for glycerol-3-phosphate dehydrogenases were disrupted after overexpressing NADH oxidase from Lactococcus lactis. As disruption of the GPD genes caused growth defects due to limited supply of C2 compounds, Candida tropicalis PDC1 was additionally introduced to provide a necessary amount of C2 compounds while minimizing ethanol production. The resulting strain (BD5_T2 nox_dGPD1,2_CtPDC1) produced 99.4 g/L of 2,3-BD with 0.5 g/L glycerol accumulation in a batch culture. The fed-batch fermentation led to production of 108.6 g/L 2,3-BD with a negligible amount of glycerol production, resulting in a high BD yield (0.462 g2,3-BD/gglucose) corresponding to 92.4 % of the theoretical yield. These results demonstrate that glycerol-free production of 2,3-BD by engineered yeast is feasible.
Asunto(s)
Butileno Glicoles/metabolismo , Eliminación de Gen , Glicerolfosfato Deshidrogenasa/genética , Saccharomyces cerevisiae/crecimiento & desarrollo , Técnicas de Cultivo Celular por Lotes , Candida tropicalis/enzimología , Fermentación , Proteínas Fúngicas/genética , Ingeniería Genética , Glicerol/metabolismo , Glicerol-3-Fosfato Deshidrogenasa (NAD+)/genética , Lactococcus lactis/enzimología , Complejos Multienzimáticos/genética , Complejos Multienzimáticos/metabolismo , NADH NADPH Oxidorreductasas/genética , NADH NADPH Oxidorreductasas/metabolismo , Piruvato Descarboxilasa/deficiencia , Saccharomyces cerevisiae/genética , Saccharomyces cerevisiae/metabolismo , Proteínas de Saccharomyces cerevisiae/genéticaRESUMEN
Saccharomyces cerevisiae is a work horse for production of valuable biofuels and biochemicals including 2,3-butanediol (2,3-BDO), a platform chemical with wide industrial applications for synthetic rubber, biosolvents and food additives. Recently, a cutting-edge technology of metabolic engineering has enabled S. cerevisiae to produce 2,3-BDO with high yield and productivity. These include (i) amplification of the 2,3-BDO biosynthetic pathway, (ii) redirection of carbon flux from ethanol or glycerol toward 2,3-BDO, and (iii) 2,3-BDO production from sugars derived from renewable biomass. These breakthroughs enforced S. cerevisiae to become a promising microbial host for production of 2,3-BDO.
Asunto(s)
Butileno Glicoles/metabolismo , Proteínas Fúngicas/genética , Regulación Fúngica de la Expresión Génica , Ingeniería Metabólica/métodos , Redes y Vías Metabólicas/genética , Saccharomyces cerevisiae/genética , Acetolactato Sintasa/genética , Acetolactato Sintasa/metabolismo , Oxidorreductasas de Alcohol/genética , Oxidorreductasas de Alcohol/metabolismo , Biocombustibles , Biomasa , Carboxiliasas/genética , Carboxiliasas/metabolismo , Etanol/metabolismo , Proteínas Fúngicas/metabolismo , Glicerol/metabolismo , Piruvato Descarboxilasa/deficiencia , Piruvato Descarboxilasa/genética , Saccharomyces cerevisiae/metabolismoRESUMEN
The use of renewable feedstocks for producing biofuels and biobased chemicals by engineering metabolic pathways of yeast Saccharomyces cerevisiae has recently become an attractive option. Many researchers attempted to increase glucose consumption rate by overexpressing some glycolytic enzymes because most target biobased chemicals are derived through glycolysis. However, these attempts have met with little success. In this study, to create a S. cerevisiae strain with high glucose consumption rate, we used multicopy integration to develop a global metabolic engineering strategy. Among approximately 350 metabolically engineered strains, YPH499/dPdA3-34 exhibited the highest glucose consumption rate. This strain showed 1.3-fold higher cell growth rate and glucose consumption rate than the control strain. Real-time PCR analysis revealed that transcription levels of glycolysis-related genes such as HXK2, PFK1, PFK2, PYK2, PGI1, and PGK1 in YPH499/dPdA3-34 were increased. Our strategy is thus a promising approach to optimize global metabolic pathways in S. cerevisiae.
Asunto(s)
Ingeniería Metabólica , Saccharomyces cerevisiae/metabolismo , Alcohol Deshidrogenasa/deficiencia , Alcohol Deshidrogenasa/genética , Dosificación de Gen , Glucosa/metabolismo , Glucólisis/genética , Hexoquinasa/genética , Hexoquinasa/metabolismo , Redes y Vías Metabólicas , Fosfofructoquinasas/genética , Fosfofructoquinasas/metabolismo , Piruvato Descarboxilasa/deficiencia , Piruvato Descarboxilasa/genética , Saccharomyces cerevisiae/genética , Saccharomyces cerevisiae/crecimiento & desarrollo , Proteínas de Saccharomyces cerevisiae/genética , Proteínas de Saccharomyces cerevisiae/metabolismoRESUMEN
Galactose and glucose are two of the most abundant monomeric sugars in hydrolysates of marine biomasses. While Saccharomyces cerevisiae can ferment galactose, its uptake is tightly controlled in the presence of glucose by catabolite repression. It is desirable to construct engineered strains capable of simultaneous utilization of glucose and galactose for producing biofuels and chemicals from marine biomass. The MTH1 gene coding for transcription factor in glucose signaling was mutated in a pyruvate decarboxylase (Pdc)-deficient S. cerevisiae expressing heterologous 2,3-butanediol (2,3-BD) biosynthetic genes. The engineered S. cerevisiae strain consumed glucose and galactose simultaneously and produced 2,3-BD as a major product. Total sugar consumption rates increased with a low ratio of glucose/galactose, though, occurrence of the glucose depletion in a fed-batch fermentation decreased 2,3-BD production substantially. Through optimizing the profiles of sugar concentrations in a fed-batch cultivation with the engineered strain, 99.1 ± 1.7 g/L 2,3-BD was produced in 143 hours with a yield of 0.353 ± 0.022 g 2,3-BD/g sugars. This result suggests that simultaneous and efficient utilization of glucose and galactose by the engineered yeast might be applicable to the economical production of not only 2,3-BD, but also other biofuels and chemicals from marine biomass.
Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/genética , Butileno Glicoles/metabolismo , Ingeniería Metabólica , Piruvato Descarboxilasa/genética , Proteínas de Saccharomyces cerevisiae/genética , Proteínas Adaptadoras Transductoras de Señales/metabolismo , Biocombustibles , Butileno Glicoles/síntesis química , Fermentación , Galactosa/metabolismo , Glucosa/metabolismo , Mutación , Piruvato Descarboxilasa/deficiencia , Piruvato Descarboxilasa/metabolismo , Saccharomyces cerevisiae/genética , Saccharomyces cerevisiae/metabolismo , Proteínas de Saccharomyces cerevisiae/metabolismoRESUMEN
Mannitol is contained in brown macroalgae up to 33% (w/w, dry weight), and thus is a promising carbon source for white biotechnology. However, Saccharomyces cerevisiae, a key cell factory, is generally regarded to be unable to assimilate mannitol for growth. We have recently succeeded in producing S. cerevisiae that can assimilate mannitol through spontaneous mutations of Tup1-Cyc8, each of which constitutes a general corepressor complex. In this study, we demonstrate production of pyruvate from mannitol using this mannitol-assimilating S. cerevisiae through deletions of all 3 pyruvate decarboxylase genes. The resultant mannitol-assimilating pyruvate decarboxylase-negative strain produced 0.86 g/L pyruvate without use of acetate after cultivation for 4 days, with an overall yield of 0.77 g of pyruvate per g of mannitol (the theoretical yield was 79%). Although acetate was not needed for growth of this strain in mannitol-containing medium, addition of acetate had a significant beneficial effect on production of pyruvate. This is the first report of production of a valuable compound (other than ethanol) from mannitol using S. cerevisiae, and is an initial platform from which the productivity of pyruvate from mannitol can be improved.
Asunto(s)
Manitol/metabolismo , Ingeniería Metabólica/métodos , Ácido Pirúvico/metabolismo , Saccharomyces cerevisiae/metabolismo , Ácido Acético/metabolismo , Eliminación de Gen , Genes Fúngicos , Cinética , Piruvato Descarboxilasa/deficiencia , Piruvato Descarboxilasa/genética , Piruvato Descarboxilasa/metabolismo , Saccharomyces cerevisiae/genética , Saccharomyces cerevisiae/crecimiento & desarrollo , Proteínas de Saccharomyces cerevisiae/genética , Proteínas de Saccharomyces cerevisiae/metabolismoRESUMEN
BACKGROUND: A Saccharomyces cerevisiae strain carrying deletions in all three pyruvate decarboxylase (PDC) genes (also called Pdc negative yeast) represents a non-ethanol producing platform strain for the production of pyruvate derived biochemicals. However, it cannot grow on glucose as the sole carbon source, and requires supplementation of C2 compounds to the medium in order to meet the requirement for cytosolic acetyl-CoA for biosynthesis of fatty acids and ergosterol. RESULTS: In this study, a Pdc negative strain was adaptively evolved for improved growth in glucose medium via serial transfer, resulting in three independently evolved strains, which were able to grow in minimal medium containing glucose as the sole carbon source at the maximum specific rates of 0.138, 0.148, 0.141 h(-1), respectively. Several genetic changes were identified in the evolved Pdc negative strains by genomic DNA sequencing. Among these genetic changes, 4 genes were found to carry point mutations in at least two of the evolved strains: MTH1 encoding a negative regulator of the glucose-sensing signal transduction pathway, HXT2 encoding a hexose transporter, CIT1 encoding a mitochondrial citrate synthase, and RPD3 encoding a histone deacetylase. Reverse engineering of the non-evolved Pdc negative strain through introduction of the MTH1 (81D) allele restored its growth on glucose at a maximum specific rate of 0.053 h(-1) in minimal medium with 2% glucose, and the CIT1 deletion in the reverse engineered strain further increased the maximum specific growth rate to 0.069 h(-1). CONCLUSIONS: In this study, possible evolving mechanisms of Pdc negative strains on glucose were investigated by genome sequencing and reverse engineering. The non-synonymous mutations in MTH1 alleviated the glucose repression by repressing expression of several hexose transporter genes. The non-synonymous mutations in HXT2 and CIT1 may function in the presence of mutated MTH1 alleles and could be related to an altered central carbon metabolism in order to ensure production of cytosolic acetyl-CoA in the Pdc negative strain.
Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/genética , Proteínas Facilitadoras del Transporte de la Glucosa/genética , Glucosa/metabolismo , Histona Desacetilasas/genética , Piruvato Descarboxilasa/deficiencia , Proteínas de Saccharomyces cerevisiae/genética , Saccharomyces cerevisiae/crecimiento & desarrollo , Saccharomyces cerevisiae/genética , Proteínas Adaptadoras Transductoras de Señales/metabolismo , Medios de Cultivo/metabolismo , Proteínas Facilitadoras del Transporte de la Glucosa/metabolismo , Histona Desacetilasas/metabolismo , Mutación , Piruvato Descarboxilasa/genética , Saccharomyces cerevisiae/enzimología , Proteínas de Saccharomyces cerevisiae/metabolismoRESUMEN
Acetyl-coenzyme A (acetyl-CoA) is not only an essential intermediate in central carbon metabolism, but also an important precursor metabolite for native or engineered pathways that can produce many products of commercial interest such as pharmaceuticals, chemicals or biofuels. In the yeast Saccharomyces cerevisiae, acetyl-CoA is compartmentalized in the cytosol, mitochondrion, peroxisome and nucleus, and cannot be directly transported between these compartments. With the acetyl-carnitine or glyoxylate shuttle, acetyl-CoA produced in peroxisomes or the cytoplasm can be transported into the cytoplasm or the mitochondria. However, whether acetyl-CoA generated in the mitochondria can be exported to the cytoplasm is still unclear. Here, we investigated whether the transfer of acetyl-CoA from the mitochondria to the cytoplasm can occur using a pyruvate decarboxylase negative, non-fermentative yeast strain. We found that mitochondrial Ach1 can convert acetyl-CoA in this compartment into acetate, which crosses the mitochondrial membrane before being converted into acetyl-CoA in the cytosol. Based on our finding we propose a model in which acetate can be used to exchange acetyl units between mitochondria and the cytosol. These results will increase our fundamental understanding of intracellular transport of acetyl units, and also help to develop microbial cell factories for many kinds of acetyl-CoA derived products.
Asunto(s)
Ácido Acético/metabolismo , Acetilcoenzima A/metabolismo , Acetil-CoA Hidrolasa/metabolismo , Coenzima A Transferasas/metabolismo , Citosol/química , Mitocondrias/enzimología , Proteínas de Saccharomyces cerevisiae/metabolismo , Saccharomyces cerevisiae/enzimología , Mitocondrias/metabolismo , Piruvato Descarboxilasa/deficiencia , Saccharomyces cerevisiae/metabolismoRESUMEN
Candida tropicalis, a diploid asporogenic yeast, is frequently utilized in industrial applications and research studies. However, the low efficiency of genetic transformation limits the strain improvement by metabolic engineering. A reliable transformation and efficient deletion of target gene are prerequisite for molecular improvement of C. tropicalis. In this study, an efficient approach for genetic transformation of C. tropicalis was developed based on the URA3 gene as a reusable selection marker and both of PDC allele genes encoding pyruvate decarboxylase were successfully deleted by this approach. Firstly, an auxotrophic mutant strain of C. tropicalis XZX which is defective in orotidine-5'-phosphate decarboxylase (URA3) was isolated by chemical mutagenesis combined with nystatin enrichment selection and 5-fluoro-orotic acid (5-FOA) resistance selection using C. tropicalis ATCC 20336 as the parent strain. Then, the first PDC deletion cassette PDC1-hisG-URA3-hisG- PDC1 (PHUHP) which contains a 1.6 kb URA3 marker gene, two copies of 1.1 kb Salmonella hisG fragments and homologous arms of target gene was constructed and transformed into C. tropicalis XZX cells. Transformants with a single copy of PDC deleted were isolated and identified by PCR and DNA sequencing, which was designated as C.tropicalis XZX02. The C.tropicalis XZX02 cells were spread on the minimal medium containing 5-FOA to generate mutant C. tropicalis XZX03 in which URA3 marker gene was excised from PHUHP fragment integrated into the PDC gene site. The second PDC gene deletion cassette PDCm-URA3-PDCm (MUM) was constructed and transformed into C. tropicalis XZX03 to generate C.tropicalis XZX04 in which both of PDC allele genes were deleted. All strains were confirmed by PCR and DNA sequencing. This efficient genetic transformation approach laid a foundation for further metabolic engineering of C. tropicalis.
Asunto(s)
Candida tropicalis/genética , Ingeniería Genética/métodos , Orotidina-5'-Fosfato Descarboxilasa/genética , Transformación Genética , Eliminación de Gen , Marcación de Gen , Marcadores Genéticos/genética , Piruvato Descarboxilasa/deficiencia , Piruvato Descarboxilasa/genéticaRESUMEN
BACKGROUND: Polylactic acid is a renewable raw material that is increasingly used in the manufacture of bioplastics, which offers a more sustainable alternative to materials derived from fossil resources. Both lactic acid bacteria and genetically engineered yeast have been implemented in commercial scale in biotechnological production of lactic acid. In the present work, genes encoding L-lactate dehydrogenase (LDH) of Lactobacillus helveticus, Bacillus megaterium and Rhizopus oryzae were expressed in a new host organism, the non-conventional yeast Candida sonorensis, with or without the competing ethanol fermentation pathway. RESULTS: Each LDH strain produced substantial amounts of lactate, but the properties of the heterologous LDH affected the distribution of carbon between lactate and by-products significantly, which was reflected in extra-and intracellular metabolite concentrations. Under neutralizing conditions C. sonorensis expressing L. helveticus LDH accumulated lactate up to 92 g/l at a yield of 0.94 g/g glucose, free of ethanol, in minimal medium containing 5 g/l dry cell weight. In rich medium with a final pH of 3.8, 49 g/l lactate was produced. The fermentation pathway was modified in some of the strains studied by deleting either one or both of the pyruvate decarboxylase encoding genes, PDC1 and PDC2. The deletion of both PDC genes together abolished ethanol production and did not result in significantly reduced growth characteristic to Saccharomyces cerevisiae deleted of PDC1 and PDC5. CONCLUSIONS: We developed an organism without previous record of genetic engineering to produce L-lactic acid to a high concentration, introducing a novel host for the production of an industrially important metabolite, and opening the way for exploiting C. sonorensis in additional biotechnological applications. Comparison of metabolite production, growth, and enzyme activities in a representative set of transformed strains expressing different LDH genes in the presence and absence of a functional ethanol pathway, at neutral and low pH, generated a comprehensive picture of lactic acid production in this yeast. The findings are applicable in generation other lactic acid producing yeast, thus providing a significant contribution to the field of biotechnical production of lactic acid.
Asunto(s)
Proteínas Bacterianas/genética , Candida/metabolismo , Proteínas Fúngicas/genética , L-Lactato Deshidrogenasa/genética , Ácido Láctico/biosíntesis , Proteínas Bacterianas/metabolismo , Etanol/metabolismo , Proteínas Fúngicas/metabolismo , L-Lactato Deshidrogenasa/metabolismo , Lactobacillus helveticus/enzimología , Lactobacillus helveticus/genética , Plásmidos/genética , Plásmidos/metabolismo , Piruvato Descarboxilasa/deficiencia , Piruvato Descarboxilasa/genética , Piruvato Descarboxilasa/metabolismoRESUMEN
Mutations in ubiquitously expressed metabolic genes often lead to CNS-specific effects, presumably because of the high metabolic demands of neurons. However, mutations in omnipresent metabolic pathways can conceivably also result in cell type-specific effects because of cell-specific requirements for intermediate products. One such example is the zebrafish noir mutant, which we found to be mutated in the pdhb gene, coding for the E1 beta subunit of the pyruvate dehydrogenase complex. This vision mutant is described as blind and was isolated because of its vision defect-related darker appearance. A detailed morphological, behavioral, and physiological analysis of the phenotype revealed an unexpected specific effect on the retina. Surprisingly, the cholinergic amacrine cells of the inner retina are affected earlier than the photoreceptors. This might be attributable to the inability of these cells to maintain production of their neurotransmitter acetylcholine. This is reflected in an earlier loss of motion vision, followed only later by a general loss of light perception. Since both characteristics of the phenotype are attributable to a loss of acetyl-CoA production by pyruvate dehydrogenase, we used a ketogenic diet to bypass this metabolic block and could indeed partially rescue vision and prolong survival of the larvae. The noir mutant provides a case for a systemic disease with ocular manifestation with a surprising specific effect on the retina given the ubiquitous requirement for the mutated gene.
Asunto(s)
Mutación/genética , Piruvato Descarboxilasa/deficiencia , Enfermedades de la Retina/diagnóstico , Enfermedades de la Retina/genética , Aminobutiratos/farmacología , Análisis de Varianza , Animales , Animales Modificados Genéticamente , Ácido Aspártico/farmacología , Colina O-Acetiltransferasa/metabolismo , Análisis Mutacional de ADN , Dieta Cetogénica/métodos , Modelos Animales de Enfermedad , Electrorretinografía/métodos , Embrión no Mamífero , Agonistas de Aminoácidos Excitadores/farmacología , Larva , Movimiento/fisiología , Nistagmo Optoquinético/genética , Nistagmo Optoquinético/fisiología , Estimulación Luminosa/métodos , Retina/citología , Retina/embriología , Retina/crecimiento & desarrollo , Retina/patología , Enfermedades de la Retina/dietoterapia , Tirosina 3-Monooxigenasa/metabolismo , Pez Cebra , Proteínas de Pez Cebra/genéticaRESUMEN
A number of fungal and oomycete plant pathogens of major economic importance feed on their hosts by means of haustoria, which they place inside living plant cells. The underlying mechanisms are poorly understood, partly due to difficulty in preparing haustoria. We have therefore developed a procedure for isolating haustoria from the barley powdery mildew fungus (Blumeria graminis f.sp. hordei, Bgh). We subsequently aimed to understand the molecular mechanisms of haustoria through a study of their proteome. Extracted proteins were digested using trypsin, separated by LC, and analysed by MS/MS. Searches of a custom Bgh EST sequence database and the NCBI-NR fungal protein database, using the MS/MS data, identified 204 haustoria proteins. The majority of the proteins appear to have roles in protein metabolic pathways and biological energy production. Surprisingly, pyruvate decarboxylase (PDC), involved in alcoholic fermentation and commonly abundant in fungi and plants, was absent in our Bgh proteome data set. A sequence encoding this enzyme was also absent in our EST sequence database. Significantly, BLAST searches of the recently available Bgh genome sequence data also failed to identify a sequence encoding this enzyme, strongly indicating that Bgh does not have a gene for PDC.
Asunto(s)
Ascomicetos/química , Proteínas Fúngicas/análisis , Hordeum/microbiología , Proteoma/análisis , Proteómica/métodos , Ascomicetos/aislamiento & purificación , Ascomicetos/metabolismo , Cromatografía Liquida , Estructuras Fúngicas/química , Estructuras Fúngicas/metabolismo , Piruvato Descarboxilasa/deficiencia , Piruvato Descarboxilasa/metabolismo , Espectrometría de Masas en TándemRESUMEN
Pyruvate decarboxylase is a key enzyme in the production of low-molecular-weight byproducts (ethanol, acetate) in biomass-directed applications of Saccharomyces cerevisiae. To investigate whether decreased expression levels of pyruvate decarboxylase can reduce byproduct formation, the PDC2 gene, which encodes a positive regulator of pyruvate-decarboxylase synthesis, was inactivated in the prototrophic strain S. cerevisiae CEN. PK113-7D. This caused a 3-4-fold reduction of pyruvate-decarboxylase activity in glucose-limited, aerobic chemostat cultures grown at a dilution rate of 0.10 h(-1). Upon exposure of such cultures to a 50 mM glucose pulse, ethanol and acetate were the major byproducts formed by the wild type. In the pdc2Delta strain, formation of ethanol and acetate was reduced by 60-70%. In contrast to the wild type, the pdc2Delta strain produced substantial amounts of pyruvate after a glucose pulse. Nevertheless, its overall byproduct formation was ca. 50% lower. The specific rate of glucose consumption after a glucose pulse to pdc2Delta cultures was about 40% lower than in wild-type cultures. This suggests that, at reduced pyruvate-decarboxylase activities, glycolytic flux is controlled by NADH reoxidation. In aerobic, glucose-limited chemostat cultures, the wild type exhibited a mixed respiro-fermentative metabolism at dilution rates above 0.30 h(-1). Below this dilution rate, sugar metabolism was respiratory. At dilution rates up to 0.20 h(-1), growth of the pdc2Delta strain was respiratory and biomass yields were similar to those of wild-type cultures. Above this dilution rate, washout occurred. The low micro(max) of the pdc2Delta strain in glucose-limited chemostat cultures indicates that occurrence of respiro-fermentative metabolism in wild-type cultures is not solely caused by competition of respiration and fermentation for pyruvate. Furthermore, it implies that inactivation of PDC2 is not a viable option for reducing byproduct formation in industrial fermentations.
Asunto(s)
Proteínas Fúngicas/genética , Proteínas Fúngicas/fisiología , Piruvato Descarboxilasa/fisiología , Proteínas de Saccharomyces cerevisiae , Saccharomyces cerevisiae/enzimología , Factores de Transcripción , Acetatos/metabolismo , Aerobiosis , División Celular , Medios de Cultivo/metabolismo , Inducción Enzimática , Etanol/metabolismo , Fermentación , Eliminación de Gen , Regulación Fúngica de la Expresión Génica , Glucosa/metabolismo , Glucólisis , NAD/metabolismo , Fenotipo , Piruvato Descarboxilasa/deficiencia , Piruvato Descarboxilasa/genética , Saccharomyces cerevisiae/genética , Saccharomyces cerevisiae/crecimiento & desarrollo , Saccharomyces cerevisiae/metabolismoRESUMEN
Pyruvate-decarboxylase (Pdc)-negative Saccharomyces cerevisiae has been reported to grow in batch cultures on glucose-containing complex media, but not on defined glucose-containing media. By a combination of batch and chemostat experiments it is demonstrated that even in complex media, Pdc- S. cerevisiae does not exhibit prolonged growth on glucose. Pdc- strains do grow in carbon-limited cultures on defined media containing glucose-acetate mixtures. The acetate requirement for glucose-limited growth, estimated experimentally by continuously decreasing the acetate feed to chemostat cultures, matched the theoretical acetyl-CoA requirement for lipid and lysine synthesis, consistent with the proposed role of pyruvate decarboxylase in the synthesis of cytosolic acetyl-CoA.
Asunto(s)
Glucosa/metabolismo , Piruvato Descarboxilasa/deficiencia , Saccharomyces cerevisiae/crecimiento & desarrollo , Acetatos/metabolismo , Acetilcoenzima A/metabolismo , Medios de Cultivo , Modelos Teóricos , Saccharomyces cerevisiae/enzimologíaAsunto(s)
Errores Innatos del Metabolismo , Piruvato Descarboxilasa/deficiencia , Biomarcadores/sangre , Diagnóstico Diferencial , Femenino , Humanos , Ácido Láctico/sangre , Masculino , Errores Innatos del Metabolismo/etiología , Errores Innatos del Metabolismo/fisiopatología , Mutación , Pronóstico , Piruvato Descarboxilasa/química , Piruvato Descarboxilasa/genética , Ácido Pirúvico/sangreRESUMEN
A comatose male newborn infant with congenital lactic acidosis caused by pyruvate decarboxylase deficiency was treated with dichloroacetate (DCA), which stimulated an 88% drop in serum lactate concentration and reversed his coma. The response to DCA was temporary and the lactic acidosis worsened until his death, but DCA may confer more lasting benefit in less severely affected infants.
Asunto(s)
Acidosis Láctica/congénito , Acidosis Láctica/tratamiento farmacológico , Ácido Dicloroacético/uso terapéutico , Piruvato Descarboxilasa/deficiencia , Errores Innatos del Metabolismo del Piruvato/tratamiento farmacológico , Acidosis Láctica/etiología , Humanos , Recién Nacido , Masculino , Errores Innatos del Metabolismo del Piruvato/complicacionesAsunto(s)
Enfermedades Metabólicas/diagnóstico , Acidosis Láctica/diagnóstico , Acidosis Láctica/orina , Grupo Citocromo b/deficiencia , Grupo Citocromo c/deficiencia , Humanos , Recién Nacido , Espectroscopía de Resonancia Magnética , Enfermedades Metabólicas/orina , Piruvato Descarboxilasa/deficiencia , Enfermedad por Deficiencia del Complejo Piruvato DeshidrogenasaAsunto(s)
Aciltransferasas/deficiencia , Carboxiliasas/deficiencia , Carnitina O-Palmitoiltransferasa/deficiencia , Carnitina/deficiencia , Metabolismo de los Lípidos , Enfermedades Musculares/etiología , Piruvato Descarboxilasa/deficiencia , Carnitina O-Palmitoiltransferasa/administración & dosificación , Femenino , Humanos , Masculino , Enfermedades Musculares/metabolismoRESUMEN
Pyruvate dehydrogenase deficiency may be a non-specific consequence of many different neurological degenerative disorders. There are also serious methodological problems in estimating the activity of this enzyme complex.
Asunto(s)
Enfermedad por Deficiencia del Complejo Piruvato Deshidrogenasa , Acetilcoenzima A/metabolismo , Acetilcoenzima A/farmacología , Acetiltransferasas/deficiencia , Acetiltransferasas/metabolismo , Acidosis/etiología , Encéfalo/patología , Dióxido de Carbono/metabolismo , Niño , Preescolar , Coenzima A/farmacología , Nervios Craneales/anomalías , Dihidrolipoamida Deshidrogenasa/deficiencia , Dihidrolipoamida Deshidrogenasa/metabolismo , Acetiltransferasa de Residuos Dihidrolipoil-Lisina , Huesos Faciales/anomalías , Retroalimentación , Humanos , Lactatos/sangre , Ácido Láctico , Enfermedad de Leigh/etiología , Peso Molecular , Trastornos del Movimiento/etiología , NAD/metabolismo , NAD/farmacología , Enfermedades del Sistema Nervioso/etiología , Monoéster Fosfórico Hidrolasas/deficiencia , Piruvato Descarboxilasa/análisis , Piruvato Descarboxilasa/deficiencia , Piruvato Descarboxilasa/metabolismo , Complejo Piruvato Deshidrogenasa/análisis , Complejo Piruvato Deshidrogenasa/metabolismo , Piruvatos/sangre , Ácido Pirúvico , EspectrofotometríaRESUMEN
We describe the successful use of sodium benzoate in a neonate with hyperammonemia associated with congenital lactic acidosis caused by a partial deficiency of the E1 component of pyruvate dehydrogenase (PDH); of note, this biochemical disturbance has not been previously described in PDH deficiency. The pyruvate dehydrogenase complex in skin fibroblasts had 48% of normal activity with a deficiency of the E1 component. The infant presented with rapid onset of a severe metabolic lactic acidosis, hyperventilation, hyperammonemia, and coma. At 30 hours of age continuous peritoneal dialysis was started; however, plasma NH3 concentrations remained in the 300-400 micrograms/dl range over the next 12 hours. Sodium benzoate, 250 mg/kg, was infused intravenously with a decrease in plasma ammonia of 25 micrograms/dl/hr. Hippurate was documented in the urine and peritoneal fluid after benzoate therapy. At 10.5 months of age, 50 mg/kg dichloroacetate was administered orally under fasting conditions, which resulted in a 56 and 62% reduction in the serum lactate and pyruvate levels, respectively; after 2 weeks on dichloroacetate his fasting levels were significantly decreased. Fibroblast PDH activity responded similarly to this drug. In our patient sodium benzoate was rapidly effective in producing a decline in plasma ammonia that was associated with clinical improvement. We feel that its use in organic acidemias deserves further evaluation and, furthermore, that any child with suspected PDH deficiency requires a clinical trial of dichloroacetate.
Asunto(s)
Acidosis/tratamiento farmacológico , Amoníaco/sangre , Benzoatos/uso terapéutico , Carboxiliasas/deficiencia , Piruvato Descarboxilasa/deficiencia , Acidosis/congénito , Acidosis/metabolismo , Benzoatos/efectos adversos , Ácido Benzoico , Ácido Dicloroacético/uso terapéutico , Hipuratos/metabolismo , Humanos , Recién Nacido , Lactatos/metabolismo , MasculinoRESUMEN
An enzymatic study of cultured skin fibroblasts was made in 28 patients with lactic acidosis. In three of these patients a diagnosis of Leigh's encephalomyelopathy was established from autopsy findings. Pyruvate decarboxylase (PDC) deficiency was found in four patients. In two of them, in whom Leigh's encephalomyelopathy was proved by autopsy, PDC activity was lower than 10% of the normal. The other two living patients, who showed 22%-25% of the normal activity, had clinical symptoms and courses different from Leigh's disease. These findings suggest that the patients with severe PDC deficiency develop Leigh's disease but those with mild deficiency may not. A deficiency of cytochrome c oxidase was found in two siblings. One of them, who was diagnosed as having Leigh's encephalomyelopathy by postmortem examination, showed a reduction of cytochrome c oxidase in the liver and brain. In the other sibling, who is living, the reduction of cytochrome c oxidase was demonstrated in the cultured skin fibroblasts and biopsied muscle. In an electron-microscopic study of biopsied muscle, two patients with mitochondrial myopathy were found. Their fundamental enzymatic defects were unclear. In two patients, in whom Leigh's disease was suspected following a brain CT, the production of 14CO2 from [3-14C] pyruvate was found to be low; suggesting a reduced activity of the TCA cycle. In another 18 patients, the fundamental defect was not clear.